Caris Life Sciences (CAI) has drawn fresh attention after reporting third quarter 2026 earnings, with revenue of US$275.36 million and earnings of US$0.05 per share, alongside a higher full year revenue outlook.
At a share price of US$33.22, Caris Life Sciences has posted a 30 day share price return of 21% and a 90 day share price return of 46.09%. The 1 year total shareholder return of 34.99% points to momentum that has been building rather than fading over time.
Spot similar momentum and fresh guidance stories to Caris Life Sciences by scanning the hand picked 38 healthcare AI stocks that focus on AI driven diagnostics and precision medicine.
This sharp move in Caris Life Sciences follows higher guidance and another quarter ahead of estimates. However, the share price now stretches above the average analyst target. Is this mainly business traction, or a changing mood around the stock?
Most Popular Narrative: 3% Overvalued
Caris Life Sciences last closed at $33.22, slightly above the most followed narrative fair value of $32.23 that is based on a 7.47% discount rate and detailed earnings, margin and revenue assumptions.
Ongoing adoption of AI across a data set of more than 959,000 genomic profiles and over 1,150 peer reviewed publications can support new assays like MI Clarity and MRD signatures. This can give Caris more content to monetize through both clinical testing and pharma work, which is relevant for sustaining revenue, maintaining high gross margins and supporting free cash flow.
See why 8 investors see Caris Life Sciences as 3% overvalued .
Result: Fair Value of $32.23 (OVERVALUED)
Still, if payers pull back on reimbursement or rival MRD and early detection platforms gain ground, the Caris Life Sciences narrative could look very different.
Find out about the key risks to this Caris Life Sciences narrative .
Another View: SWS DCF Model Points To Underpricing
The analyst narrative has Caris Life Sciences trading about 3% above its fair value of $32.23. Our DCF model points in the other direction. On this view, the shares at $33.22 sit about 14.3% below an estimated future cash flow value of $38.77. This frames recent enthusiasm as less frothy and more like investors catching up.
For readers who want to see how the cash flow math stacks up against the narrative numbers, Look into how the SWS DCF model arrives at its fair value. .
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Caris Life Sciences for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 35 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Sentiment around Caris Life Sciences is clearly split, which is exactly why you should move quickly, test the assumptions against the data, and weigh the 3 key rewards and 2 important warning signs .
Looking for more investment ideas beyond Caris Life Sciences?
If you like the setup around Caris Life Sciences, do not stop here. Broaden your opportunity set and let the data surface your next move.
-
Target potential mispricings by scanning the 35 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect underlying business quality.
-
Build a steadier income stream by reviewing the 5 dividend fortresses that focus on higher yielding companies with the potential to support regular payouts.
-
Dial down portfolio stress by assessing the 31 resilient stocks with low risk scores and concentrate on businesses with more resilient balance sheet and risk profiles.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CAI .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
